KCL-286

Modify Date: 2024-08-09 17:45:20

KCL-286 Structure
KCL-286 structure
Common Name KCL-286
CAS Number 1952276-71-9 Molecular Weight 334.33
Density N/A Boiling Point N/A
Molecular Formula C19H14N2O4 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of KCL-286


Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI)[1].

 Names

Name KCL-286

 KCL-286 Biological Activity

Description Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI)[1].
Related Catalog
Target

RAR β2[1]

References

[1]. Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..  

 Chemical & Physical Properties

Molecular Formula C19H14N2O4
Molecular Weight 334.33
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.